Drug Profile
Recombinant human HER2 monoclonal antibody - Anhui Anke Biotechnology
Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Anhui Anke Biotechnology
- Developer Anhui Anke Biotechnology; Peking University People's Hospital
- Class Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Breast-cancer(In volunteers) in China (Injection)
- 22 Feb 2021 Phase-I development is ongoing China (ChiCTR-IIR16009808)
- 28 May 2019 No recent reports of development identified for phase-I development in Breast-cancer(In volunteers) in China (Injection)